These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 35306339

  • 1. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
    Lei WT, Chang LS, Zeng BY, Tu YK, Uehara R, Matsuoka YJ, Su KP, Lee PC, Cavalcante JL, Stubbs B, Lin PY, Wu YC, Hsu CW, Chen TY, Chen YW, Yeh PY, Sun CK, Tseng PT, Kao YH.
    EBioMedicine; 2022 Apr; 78():103946. PubMed ID: 35306339
    [Abstract] [Full Text] [Related]

  • 2. Intravenous immunoglobulin for the treatment of Kawasaki disease.
    Broderick C, Kobayashi S, Suto M, Ito S, Kobayashi T.
    Cochrane Database Syst Rev; 2023 Jan 25; 1(1):CD014884. PubMed ID: 36695415
    [Abstract] [Full Text] [Related]

  • 3. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
    Pediatrics; 2004 Dec 25; 114(6):e689-93. PubMed ID: 15545617
    [Abstract] [Full Text] [Related]

  • 4. Kawasaki disease: a comprehensive review of treatment options.
    Patel RM, Shulman ST.
    J Clin Pharm Ther; 2015 Dec 25; 40(6):620-5. PubMed ID: 26547265
    [Abstract] [Full Text] [Related]

  • 5. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
    Eleftheriou D, Moraes YC, Purvis C, Pursell M, Morillas MM, Kahn R, Mossberg M, Kucera F, Tulloh R, Standing JF, Swallow V, McCormack R, Herberg J, Levin M, Wan M, Klein N, Connon R, Walker AS, Brogan P.
    Trials; 2023 Jan 26; 24(1):60. PubMed ID: 36703139
    [Abstract] [Full Text] [Related]

  • 6. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
    Burns JC, Roberts SC, Tremoulet AH, He F, Printz BF, Ashouri N, Jain SS, Michalik DE, Sharma K, Truong DT, Wood JB, Kim KK, Jain S, KIDCARE Multicenter Study Group.
    Lancet Child Adolesc Health; 2021 Dec 26; 5(12):852-861. PubMed ID: 34715057
    [Abstract] [Full Text] [Related]

  • 7. Corticosteroids for the treatment of Kawasaki disease in children.
    Wardle AJ, Connolly GM, Seager MJ, Tulloh RM.
    Cochrane Database Syst Rev; 2017 Jan 27; 1(1):CD011188. PubMed ID: 28129459
    [Abstract] [Full Text] [Related]

  • 8. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH.
    PLoS One; 2015 Jan 27; 10(12):e0144603. PubMed ID: 26658843
    [Abstract] [Full Text] [Related]

  • 9. Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease.
    Chan H, Chi H, You H, Wang M, Zhang G, Yang H, Li Q.
    BMC Pediatr; 2019 May 17; 19(1):158. PubMed ID: 31101091
    [Abstract] [Full Text] [Related]

  • 10. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
    Roberts SC, Jain S, Tremoulet AH, Kim KK, Burns JC, KIDCARE Multicenter Study Group, Anand V, Anderson M, Ang J, Ansusinha E, Arditi M, Ashouri N, Bartlett A, Chatterjee A, DeBiasi R, Dekker C, DeZure C, Didion L, Dominguez S, El Feghaly R, Erdem G, Halasa N, Harahsheh A, Jackson MA, Jaggi P, Jain S, Jone PN, Kaushik N, Kurio G, Lillian A, Lloyd D, Manaloor J, McNelis A, Michalik DE, Newburger J, Newcomer C, Perkins T, Portman M, Romero J, Ronis T, Rowley A, Schneider K, Schuster J, Tejtel SKS, Sharma K, Simonsen K, Szmuszkovicz J, Truong D, Wood J, Yeh S.
    Contemp Clin Trials; 2019 Apr 17; 79():98-103. PubMed ID: 30840903
    [Abstract] [Full Text] [Related]

  • 11. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
    Li X, Tang Y, Ding Y, Chen Y, Hou M, Sun L, Qian G, Qin L, Lv H.
    Eur J Pharmacol; 2021 May 15; 899():173985. PubMed ID: 33652059
    [Abstract] [Full Text] [Related]

  • 12. Corticosteroids for the treatment of Kawasaki disease in children.
    Green J, Wardle AJ, Tulloh RM.
    Cochrane Database Syst Rev; 2022 May 27; 5(5):CD011188. PubMed ID: 35622534
    [Abstract] [Full Text] [Related]

  • 13. Efficacy between low and high dose aspirin for the initial treatment of Kawasaki disease: Current evidence based on a meta-analysis.
    Zheng X, Yue P, Liu L, Tang C, Ma F, Zhang Y, Wang C, Duan H, Zhou K, Hua Y, Wu G, Li Y.
    PLoS One; 2019 May 27; 14(5):e0217274. PubMed ID: 31117119
    [Abstract] [Full Text] [Related]

  • 14. Low-dose or no aspirin administration in acute-phase Kawasaki disease: a meta-analysis and systematic review.
    Chiang MH, Liu HE, Wang JL.
    Arch Dis Child; 2021 Jul 27; 106(7):662-668. PubMed ID: 33172886
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness of intravenous immunoglobulin alone and intravenous immunoglobulin combined with high-dose aspirin in the acute stage of Kawasaki disease: study protocol for a randomized controlled trial.
    Kuo HC, Guo MM, Lo MH, Hsieh KS, Huang YH.
    BMC Pediatr; 2018 Jun 22; 18(1):200. PubMed ID: 29933749
    [Abstract] [Full Text] [Related]

  • 16. Recent advances in the treatment of Kawasaki disease.
    Weng KP, Ou SF, Lin CC, Hsieh KS.
    J Chin Med Assoc; 2011 Nov 22; 74(11):481-4. PubMed ID: 22100015
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group.
    Lancet Child Adolesc Health; 2018 Dec 22; 2(12):855-862. PubMed ID: 30337183
    [Abstract] [Full Text] [Related]

  • 18. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR.
    Pediatr Infect Dis J; 2018 Oct 22; 37(10):976-980. PubMed ID: 29461447
    [Abstract] [Full Text] [Related]

  • 19. Effects of immunoglobulin plus prednisolone in reducing coronary artery lesions in patients with Kawasaki disease: study protocol for a phase III multicenter, open-label, blinded-endpoints randomized controlled trial.
    Lin SY, He L, Xie LP, Wang Y, Lin YX, Cao YY, Yan WL, Liu F, Huang GY.
    Trials; 2021 Dec 11; 22(1):898. PubMed ID: 34895290
    [Abstract] [Full Text] [Related]

  • 20. Reevaluation of the efficacy of intravenous gammaglobulin in the prevention and treatment of coronary artery lesion in Kawasaki disease.
    Qin L, Saumu MT, Wang H, Shi H, Hu X, Cheng P.
    J Huazhong Univ Sci Technolog Med Sci; 2005 Dec 11; 25(3):348-50, 370. PubMed ID: 16201293
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.